Abstract:At least 10% of all breast cancer is estimated to result from an inherited predisposition.1 Mutations in 2 genes, BRCA1 and BRCA2, have been shown to confer a very high risk for breast and ovarian cancer.2 A significant proportion of familial cases, however, cannot be attributed to BRCA1 or BRCA2 mutations,3, 4 and additional breast cancer susceptibility gene(s) may account for a fraction of high-risk families. Recently, it was suggested that a novel protein, BACH1, a member of the DEAH helicase family could be one such gene.5 BACH1 maps to 17q22 and consists of 20 exons, spanning over 180 kb of genomic sequence. It encodes a 130 kDa polypeptide that binds directly to BRCT repeats of BRCA1 and interferes with normal double-strand break repair in a manner that was dependent on the BRCA1 binding.5 Furthermore, 2 germ-line missense mutations were detected in 65 individuals with breast cancer (1 in familial and 1 with early-onset breast cancer) lacking mutations in both BRCA1 and BRCA2. None of them occurred in any of 200 normal controls. We have evaluated a putative contribution of this locus to breast cancer susceptibility by analyzing 197 breast cancer families in which we did not detect BRCA1 and BRCA2 mutations (Table I). The exon 11 of BRCA1 was screened on genomic DNA using PTT and the remaining exons were analyzed using SSCP, CDGE or direct sequencing.4, 6 The BRCA2 gene was screened by PTT using genomic DNA for exon 10 and 11 and using RNA for all other exons, or the entire gene was screened using direct sequencing of genomic DNA.4, 7 High-risk breast cancer families were identified and collected through the Cancer Counseling Clinic at the Karolinska Hospital. The families were selected if 2 or more close relatives were affected with breast cancer, and if the proband was counseled a 2–4 times increased risk for the disease compared to the normal population. Blood samples were obtained from the affected and unaffected family members with informed consent. Linkage analysis involved 285 members of 102 breast cancer families, including 245 breast cancer patients. The average age at diagnosis in the patients was 54.7 years old, ranging between 30–72. Nine of the families were breast-ovarian cancer families. Additional 95 patients with a family history of breast cancer, negative for BRCA1 and BRCA2 mutations, were selected to be screened for mutations in the BACH1 gene. Control females were mothers of Swedish patients with IgA deficiency ascertained as described previously8 and apparently unrelated blood donors drawn from the Swedish population. Genotyping was carried out using 19 fluorescent-labeled microsatellite markers on chromosome 17 (D17S1308; D17S1845; D17S1810; D17S1298; D17S1832; D17S974; D17S1303; D17S969; D17S921; D17S122; D17S1294; D17S1293; D17S1299; D17S809;D17S1290; D17S31B11; D17S1301; D17S784; D17S928), including 3 markers flanking the BACH1 gene (underlined). The amplified fragments were analyzed on an ABI377 automated sequencer (Applera, USA), together with internal size standard. The gels were analyzed with GENESCAN (v.3.1) and GENOTYPER (v.2.0) software packages (Applera). The average heterozygosity of markers was 0.76 with an average intermarker genetic distance of 7.8 cM. Nonparametric and multipoint linkage analysis was performed by using Genehunter (v.2.0) program.9 The genetic linkage analysis showed negative multipoint nonparametric LOD scores (NPL) for markers around BRCA1 and BRCA2 in 73 of 102 breast cancer and breast-ovarian cancer families. Only 29 families, including 3 early onset breast-ovarian cancer families, showed a positive NPL for markers flanking the BACH1 locus. A positive NPL indicates that the affected individuals in the pedigree share alleles at the analyzed loci in excess, which makes this region more likely to harbor a predisposing gene. Thus, the 29 families were selected and screened for germline mutations in the BACH1 gene, together with additional 95 familial breast cancer cases without detectable BRCA1 and BRCA2 mutations (Table I). Twenty-four segments of BACH1 coding exons and flanking intronic sequences were amplified from genomic DNA. The average size of PCR products was 247 bp, with a range of 164–331 bp. Oligonucleotide primers and PCR conditions are shown at http://www.biosci.ki.se/fam/res/BACH1.htm. The PCR-SSCP analysis and nucleotide sequencing was carried out as described.10 The PCR-SSCP analysis showed 4 different alterations. Three alterations turned out to be known polymorphisms (Table II), 5 whereas 1 alteration was a 517C-T transition not previously reported (Table II). This rare variant, which results in Arg173Cys substitution in the putative nuclear localization signal of BACH1, as predicted by PSORTII,11 was found in a family where 5 women were diagnosed with breast cancer. The variant was identified in 1 woman with breast cancer at age 51 but was not shared by her daughter who had breast cancer at age 45. Although this alteration did not segregate with disease in this family, it might still represent a weak disease-predisposition allele in the general population. To address this question, unrelated breast cancer patients and control females from the same population were examined. Three of 478 Swedish breast cancer patients (0.6%) and 2 of 315 Swedish controls (0.6%) were found to be heterozygous for this transition. No homozygotes were identified and there was no significant deviation from Hardy-Weinberg equilibrium (p > 0.05). These results suggested a similar allele/genotype frequency in affected and control individuals (p > 0.05), consistent with this alteration being a rare polymorphism that confers no detectable risk to breast cancer. Because of the low frequency of the variant allele, however, functional and larger association studies will be needed to elucidate a putative significance of this polymorphism in breast cancer. The families studied were previously screened for BRCA1-2 using various techniques, including PTT, SSCP, CDGE or by direct sequencing of all exons for both genes. Regardless of methods used, the frequency of BRCA-mutations in this cohort of patients has been low.4 At the same time, the age of onset of familial breast cancer in the Stockholm region is not, in contrast to what has been described in familial breast cancer in general, very much different from the age of onset in sporadic cases.12 The study involves a proportion of families with only 2 close relatives with breast cancer consistent with an increased susceptibility for disease, but also consistent with a genetic trait with low penetrance. In some of the families it is possible that these 2 cases were sporadic and occurred by chance. However, these families constitute a minority (20%), which is why this could not be the explanation for the lack of mutations found in this study. In conclusion, we found no BACH1 mutation in this highly selected family material, which would be predicted to be enriched for mutated cases by our linkage and family data, should BACH1 be an important breast cancer susceptibility gene. Recently, it was suggested that a few moderately strong genes and large number of weak genes together were responsible for breast cancer,2 thus not excluding the involvement of BACH1 in rare cases of breast- and ovarian cancer. Comparing the allelic and genotype frequency of BACH1 variants between much large numbers of breast cancer cases and matched normal population with minimized influence of the population stratification are needed to address a putative influence of this gene. Yours Sincerely, Liping LUO, Haixin LEI, Quan DU, Anna VON-WACHENFELDT, Ingrid KOCKUM, Holger LUTHMAN, Igor VORECHOVSKY and ANNIKA LINDBLOM* We thank the patients and their family members for cooperation.

No Mutations in the BACH1 Gene in BRCA1 and BRCA2 Negative Breast‐cancer Families Linked to 17Q22

[Analysis of the Mutations of BRCA1 in 9 Familiar Breast Cancer Patients].

Abstract P2-09-03: Spectrum, Prevalence and Clinical Outcomes of Germline Mutations in PALB2 Genes in 16501 Unselected BRCA1/2-negative Breast Cancer Patients: A Multi-Center Analysis

Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives

No Evidence for a Familial Breast Cancer Susceptibility Gene at Chromosome 13q21 in Swedish Breast Cancer Families

Spectrum, prevalence and clinical outcomes of germline mutations in PALB2 genes in 16501 unselected BRCA1/2-negative breast cancer patients: A multi-center analysis

Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families

A Population-Based Study of Genes Previously Implicated in Breast Cancer.

Abstract PD3-01: Population-based breast cancer risk estimates for predisposition gene mutations: Results from the CARRIERS study

A common coding variant in CASP8 is associated with breast cancer risk

Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes

Uncovering BTB and CNC Homology1 (BACH1) as a Novel Cancer Therapeutic Target

Abstract P3-07-07: Single nucleotide polymorphisms of BRCA1-interacting genes are associated with triple-negative breast cancer in Chinese Han woman

The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants

[BRCA1 Germ Line Mutations in Chinese Early-Onset Breast Cancer Patients].

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

[Analysis of Mutation Sites of BRCA1 Gene in Chinese Patients with Breast Cancer].

Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer

Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

Benign polymorphisms in the BRCA genes with linkage disequilibrium is associated with cancer characteristics